Here we go again… just as the economy was getting back on its feet, along comes Omicron and more government restrictions to drag us back down.
It is often said that we should be willing to pay any economic price to control Covid. However, it is essential to take account of the potential costs, and not just any benefits, in assessing whether the case for new measures adds up.
The economic costs of the new restrictions depend on two things. First, there is the direct impact of the individual measures themselves. The new guidance on ‘working from home’ and the rollout of ‘vaccine passports’ will have a substantial impact on office-related activities and on the leisure and hospitality sectors.
Second, there is the broader impact on sentiment. Even if each new regulation in isolation is only a small change from where we are now, it’s the cumulative impacts and the direction of travel that really matter. This could have a chilling impact on consumer and business confidence, and on spending.
It is hard to put firm numbers on this, but someone has to. Judging by what happened last winter, the additional Covid restrictions could knock as much as 2 per cent off GDP – costing the UK economy at least £4 billion a month. The additional restrictions could also force the taxpayer to stump up billions more to prevent a new wave of bankruptcies and job losses.
This isn’t just about the economy, either. These economic costs would come on top of all the social costs and harms to people’s wellbeing and liberties.
Many reasonable people will still argue that these costs are worth it, to buy time for the NHS and for the vaccine booster programme. Even just thinking about the economics, it could make sense to take another hit in the short term to secure a stronger recovery in the longer term.
However, this judgement would require strong evidence that the new variant is more deadly, not just more transmissible. This is a particularly high bar to clear in the UK, where most experts agree that the population has now acquired a high degree of immunity due to past infections and from the vaccines already delivered.
So far, this evidence base is missing. At the very least, the government needs to be willing to review the new ‘Plan B’ restrictions sooner rather than later, as we learn more about the risks posed (or not posed) by Omicron.
Julian Jessop
Economics Fellow, Institute of Economic Affairs
|